PROCEPT BioRobotics (PRCT) Projected to Post Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to be issuing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.32) per share and revenue of $93.7040 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

PROCEPT BioRobotics Trading Down 1.1%

Shares of PROCEPT BioRobotics stock opened at $27.79 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44. The firm has a 50-day moving average of $31.48 and a 200-day moving average of $34.50. PROCEPT BioRobotics has a 52-week low of $26.66 and a 52-week high of $70.80. The stock has a market cap of $1.55 billion, a PE ratio of -18.16 and a beta of 0.99.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PRCT shares. Jefferies Financial Group upgraded shares of PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research report on Friday, December 12th. UBS Group assumed coverage on PROCEPT BioRobotics in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price target for the company. Leerink Partners reissued an “outperform” rating and set a $55.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a report on Tuesday, December 2nd. Finally, Bank of America reiterated a “neutral” rating and set a $38.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.40.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently modified their holdings of the business. Prosight Management LP grew its position in PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock valued at $43,415,000 after acquiring an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. UBS Group AG grew its holdings in shares of PROCEPT BioRobotics by 129.3% during the 3rd quarter. UBS Group AG now owns 944,545 shares of the company’s stock valued at $33,711,000 after purchasing an additional 532,530 shares during the last quarter. Marshall Wace LLP increased its position in PROCEPT BioRobotics by 9,100.2% during the 3rd quarter. Marshall Wace LLP now owns 381,534 shares of the company’s stock worth $13,617,000 after purchasing an additional 377,387 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in PROCEPT BioRobotics by 87.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 517,732 shares of the company’s stock valued at $16,288,000 after purchasing an additional 241,863 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.